Hill Dermaceuticals, Inc. v. Rx Solutions

306 F. App'x 450
Court of Appeals for the Eleventh Circuit·Decided December 17, 2008·No. 08-13333·Unpublished

Opinion

PER CURIAM:

Hill Dermaceuticals, Inc. appeals the dismissal of its amended complaint against Prescription Solutions, United Health Group, and United Healthcare of Florida. Hill challenges the denial of its motion to remand and the dismissal of its complaint that Prescription Solutions made false and misleading statements to third parties about a product of Hill, Derma-Smoothe. We affirm.

I. BACKGROUND

Prescription Solutions is a California-based pharmacy benefit manager that oversees prescription drug benefits for persons insured by managed care organizations. United Healthcare of Florida, an insurance company in Florida, contracted with Prescription Solutions to administer the drug formulary for its members. Both Prescription Solutions and United Healthcare are owned by United Health Group, a Minneapolis corporation.

Hill is a Florida corporation that manufactures and distributes DermaSmoothe/FS body oil, a product marketed to treat eczema, atopic dermatitis, and psoriasis that affects between 50 and 90 percent of the body. Hill markets DermaSmoothe as the only FDA-approved corticosteroid ointment for the treatment of systemic skin conditions. Derma-Smoothe is not on the formulary of Prescription Solutions.

*452 In November 2007, Hill filed a complaint in a Florida court that alleged tortious conduct by Prescription Solutions, as an alter-ego or agent of United Healthcare, and their alleged parent companies, United Healthcare Company and Pacific Health Systems. Hill complained that Prescription Solutions made statements about Derma-Smoothe that constituted an injurious falsehood, defamation, misleading advertising, and a deceptive and unfair trade practice. Hill alleged that all insurance companies were “required to cover Derma-Smoothe” and the suggestion that patients and physicians use an alternative medication constituted “false, deceptive, misleading and fraudulent information” about Derma-Smoothe.

Prescription Solutions and United Healthcare removed the action to federal court. The companies alleged that the district court had removal jurisdiction, 28 U.S.C. § 1441, based on a federal question, id. § 1381, and diversity of citizenship, id. § 1332. The companies also alleged that Hill fraudulently joined United Healthcare to defeat diversity jurisdiction.

Prescription Solutions and United Healthcare moved to dismiss the complaint for failure to state a claim and Hill moved to remand. The district court dismissed Hill’s complaint without prejudice. Prescription Solutions and United Healthcare did not respond to Hill’s motion to remand.

In the interim, Hill filed an amended complaint that named Prescription Solutions, United Healthcare, and United Health Group as defendants and accused the companies of the same tortious conduct alleged in the original complaint. Hill based its complaints on two letters allegedly distributed by Prescription Solutions to unidentified parties regarding its payment for coverage of Derma-Smoothe. Hill alleged that the letters notified patients and physicians that Derma-Smoothe was not on the formulary of Prescription Solutions and was not covered by insurance unless a patient was intolerant to clobetasol, triamcinolone, and hydrocortisone. One letter allegedly stated,

Based on the information provided by you or your physician, you do not meet the established medical necessity criteria or guidelines for [Derma-Smoothe] at this time. [Derma-Smoothe] is denied. This drug is not on our formulary, coverage requires a contraindication, failure or intolerance to the following formulary agents: triamcinolone, clobetasol, or hydrocortisone.

A second letter allegedly stated, “[Derma-Smoothe] is not on our formulary, coverage requires a contraindication, failure or intolerance to all of the formulary agents: clobetasol, triamcinolone, and hydrocortisone. Based on the clinical information provided, a trial on triamcinolone and hydrocortisone [is] required.”

Five days later, the district court granted Hill’s motion to remand. The district court granted the motion under “Local Rule 3.01(b)” because it was “unopposed.” Prescription Solutions and United Healthcare moved for reconsideration, and the district court denied the motion.

United Health Group removed the action on the identical grounds stated by Prescription Solutions and United Healthcare in them motion to remove. Hill again moved to remand. After a hearing, the district court denied the motion to remand. The district court ruled that Hill had fraudulently joined United Healthcare in the amended complaint to defeat diversity of citizenship.

Hill later moved to amend the complaint to include a request for declaratory judgment. Hill attached to the second amended complaint an affidavit executed by Doctor Randall Coverman. Dr. Coverman *453 stated that he had prescribed DermaSmoothe and Prescription Solutions had denied coverage on the ground that Derma-Smoothe was not on the drug formulary. Dr. Coverman also stated that Prescription Solutions had notified his patient that Derma-Smoothe was a covered medication only if the patient had a “contraindication, failure or interolerance to” its “formulary agent(s) ... triamcinoline, clobetasol, or hydrocortisone.” Dr. Coverman stated that the denial had “forced [him] into a position of having to choose a drug other than Derma-Smoothe ... my drug of choice.”

Prescription Solutions and United Healthcare moved to dismiss the second amended complaint for failure to state a claim. The district court found that “further amendments would be futile” and dismissed Hill’s complaint with prejudice.

II. STANDARDS OF REVIEW

We review de novo issues of subject-matter jurisdiction. Bailey v. Janssen Pharmaceutica, Inc., 536 F.3d 1202, 1204 (11th Cir.2008). We also review de novo the dismissal of a complaint for failure to state a claim and accept the allegations in the complaint as true and construe them in the light most favorable to the plaintiff. Glover v. Liggett Group, Inc., 459 F.3d 1304, 1308 (11th Cir.2006). “We have jurisdiction to consider [the] denial of a motion to remand” after dismissal of a complaint with prejudice. Bailey, 536 F.3d at 1204. “ ‘As a general rule, an appellate court will not review a legal issue or theory not presented to the trial court, unless the issue is a pure question of law and the court’s failure to consider it would result in a miscarriage of justice.’ ” Sierra Club, Inc. v. Leavitt, 488 F.3d 904, 912 (11th Cir.2007) (quoting NAACP v. Hunt, 891 F.2d 1555,1563 (11th Cir.1990)).

III. DISCUSSION

Hill makes two arguments on appeal. First, Hill argues that the district court erred by denying the second motion to remand.

Free access — add to your briefcase to read the full text and ask questions with AI

Hill Dermaceuticals, Inc. v. Rx Solutions, 306 F. App'x 450 (11th Cir. 2008).

306 F. App'x 450 (Hill Dermaceuticals, Inc. v. Rx Solutions) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Untitled Case
M.D. Florida, 2026